Colombia vs Congo, Democratic Republic of the: Access to anti-retroviral drugs, female
Colombia
77.0%
in 2023
Congo, Democratic Republic of the
78.0%
in 2024
Colombia rank
63rd
Congo, Democratic Republic of the rank
60th
Access to anti-retroviral drugs, female over time
- Colombia
- Congo, Democratic Republic of the
How they compare
Congo, Democratic Republic of the currently reports 78.0% against 77.0% in Colombia, a difference of 1.0%.
The two have swapped places 2 times across 24 shared years of data; in 2000 it was Congo, Democratic Republic of the ahead.
Colombia ranks 63rd and Congo, Democratic Republic of the ranks 60th of 141 countries.
Colombia has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Colombia | Congo, Democratic Republic of the | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 8.2% | 2.0% | 6.2% | Colombia |
| 2010s | 52.0% | 25.7% | 26.3% | Colombia |
| 2020s | 75.5% | 68.2% | 7.2% | Colombia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Colombia or Congo, Democratic Republic of the?
- Congo, Democratic Republic of the, at 78.0% against 77.0% in Colombia as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Colombia and Congo, Democratic Republic of the?
- 1.0%, with Congo, Democratic Republic of the ahead.
- How many years of comparable data are there for Colombia and Congo, Democratic Republic of the?
- 24 years are reported by both, from 2000 to 2023.
- How do Colombia and Congo, Democratic Republic of the rank globally for access to anti-retroviral drugs, female?
- Colombia ranks 63rd and Congo, Democratic Republic of the ranks 60th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.